Bleeding following Endoscopic Submucosal Dissection for Early Gastric Cancer in Surgically Altered Stomach

Hiroyuki Odagiri, Waku Hatta, Yosuke Tsuji, Toshiyuki Yoshio, Yohei Yabuuchi, Daisuke Kikuchi, Shigetsugu Tsuji, Yasuaki Nagami, Takuto Hikichi, Masakuni Kobayashi, Yoshinori Morita, Tetsuya Sumiyoshi, Mikitaka Iguchi, Hideomi Tomida, Takuya Inoue, Tatsuya Mikami, Kenkei Hasatani, Jun Nishikawa, Hiroko Nebiki, Dai Nakamatsu, Ken Ohnita, Haruhisa Suzuki, Hiroya Ueyama, Yoshiho Hayashi, Mitsuhige Sugimoto, Shinjiro Yamaguchi, Tomoki Michida, Tomoyuki Yada, Yoshiro Asahina, Toshiaki Narasaka, Shioko Kuribayashi, Shu Kiyotoki, Katsuhiro Mabe, Mitsuhiro Fujishiro, Atsushi Masamune, Shu Hoteya

Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan; Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Gastroenterology, The University of Tokyo, Tokyo, Japan; Division of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Kobe City Medical Center General Hospital, Kobe, Japan; Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan; Department of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan; Department of Gastroenterology, The Jikei University School of Medicine, Tokyo, Japan; Department of Gastroenterology, Kobe University International Clinical Cancer Research Center, Kobe, Japan; Department of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan; Department of Gastroenterology, Tonan Hospital, Sapporo, Japan; Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan; Department of Gastroenterology and Metabolology, Ehime University Graduate School of Medicine, Toon, Japan; Division of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan; Division of Endoscopy, Hirosaki University Hospital, Hirosaki, Japan; Department of Gastroenterology, Fukui Prefectural Hospital, Fukui, Japan; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan; Department of Gastroenterology, Chiba University Graduate School of Medicine, Chiba, Japan; Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan; Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan; Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan; Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan; Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan; Division of Digestive Endoscopy, Shiga University of Medical Science Hospital, Otsu, Japan; Division of Gastroenterology, Kansai Rosai Hospital, Amagasaki, Japan; Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama, Japan; Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan; Division of Gastroenterology and Hepatology, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan; Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan; Division of Endoscopic Center, University of Tsukuba Hospital, Tsukuba, Japan; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan; Department of Gastroenterology, Shuto General Hospital, Yanai, Japan; Department of Gastroenterology, National Hospital Organization Hakodate National Hospital, Hakodate, Japan; Junpukai Health Maintenance Center Kurashiki, Kurashiki, Japan

© 2022 The Author(s).
Published by S. Karger AG, Basel
www.karger.com/dig

This is an Open Access article licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense), applicable to the online version of the article only. Usage and distribution for commercial purposes requires written permission.

Correspondence to: Waku Hatta, waku-style@festa.ocn.ne.jp
Keywords
Bleeding · Endoscopic submucosal dissection · Early gastric cancer · Surgically altered stomach

Abstract

Introduction: Few studies have focused on bleeding following endoscopic submucosal dissection (ESD) in surgically altered stomach. We aimed to reveal the bleeding risk in surgically altered stomach following ESD for early gastric cancer (EGC). Methods: We enrolled patients with ESD for EGC at 33 institutions between 2013 and 2016. In study 1, we evaluated bleeding risk following ESD in surgically altered stomach, compared with whole stomach. In study 2, we evaluated factors associated with bleeding following ESD in patients with surgically altered stomach. Results: Of 11,452 patients, 445 patients had surgically altered stomach with the bleeding rate following ESD of 4.9%. In study 1, the bleeding risk in surgically altered stomach was not significant (odds ratio [OR], 1.37; 95% confidence interval [CI], 0.87–2.17) in the multivariate logistic regression analysis. No significant results were obtained when the surgically altered stomach was subdivided into various types. In study 2, the multivariate logistic regression analysis revealed that independent risk factors for bleeding following ESD were ischemic heart disease (OR, 7.52; 95% CI, 2.00–28.25) and P2Y12 receptor antagonist (OR, 4.81; 95% CI, 1.21–19.14). Discussion/Conclusion: In this nationwide study, we found that the bleeding risk of surgically altered stomach following ESD for EGC did not significantly differ from that of whole stomach. The risk factors for ESD in patients with surgically altered stomach were ischemic heart disease and P2Y12 receptor antagonist.

© 2022 The Author(s).
Published by S. Karger AG, Basel

Introduction

Endoscopic resection for early gastric cancer (EGC) has been accepted as a minimally invasive treatment [1–4], and it achieves a favorable prognosis regardless of its curability [5–7]. Compared with endoscopic mucosal resection, endoscopic submucosal dissection (ESD) is advantageous because it allows en bloc resection for precise histopathological evaluation regardless of lesion size and configuration, resulting in a lower local recurrence rate [3, 8].

For patients with EGC in the remnant stomach or gastric conduit, the role of ESD may be more important because a surgical approach, in which total gastrectomy is generally selected [9], is highly invasive and impairs the postoperative quality of life. Meanwhile, although many studies have investigated bleeding following gastric ESD in patients with whole stomach [10–12], few studies have focused on bleeding following ESD in patients with surgically altered stomach. A recent systematic review reported the bleeding rate following gastric ESD in patients with surgically altered stomach as 5.3% [13], but the details of bleeding following ESD in such patients (e.g., difference in the bleeding risk among various types of surgically altered stomach, risk factors for bleeding) remain unclear. Furthermore, no studies directly compared the bleeding risk between surgically altered and whole stomach under similar baseline characteristics. All previous studies were single-institution studies with relatively small numbers of cases [14–21], which may have made it difficult to clarify the details of bleeding following gastric ESD in patients with surgically altered stomach.

Recently, we conducted a nationwide multicenter retrospective study to establish a prediction model for bleeding following ESD for EGC (BEST-J score) in patients with whole stomach [22]. This study included over 10,000 cases, and several findings about bleeding following ESD have been clarified by using this database [23–28]. However, these studies did not include patients with surgically altered stomach and, thus, no findings about surgically altered stomach have been clarified in this database. The aim of the present study was to reveal the bleeding risk of surgically altered stomach following ESD for EGC.

Materials and Methods

Patient Selection and Data

This is a sub-analysis of a recent multicenter retrospective study [22]. This study included patients who experienced ESD for EGC at 33 institutions in Japan between November 2013 and October 2016. Among them, patients who did not meet the exclusion criteria were enrolled in the present study. The exclusion criteria were as follows: (i) ESD was not completed, (ii) follow-up duration was less than 28 days following ESD, (iii) the ulcer was closed or covered with polyglycolic acid sheets and fibrin glue following ESD, (iv) clinical data were not available due to patient refusal, (v) photodynamic therapy following ESD was performed, and (vi) invasion of the muscularis propria or deeper tissue was observed pathologically (Fig. 1). In the present study, all terminology and classification of tumor size, macroscopic type, histological type, and depth of tumor invasion were in accordance with the Japanese classification of gastric carcinoma [29]. The present study was conducted according to the guidelines of the Declaration of Helsinki and was approved by each institution’s review board.

ESD Procedure

ESD was performed according to a standard technique at all institutions, and the details of the ESD procedures have been described elsewhere [30]. After excision of the lesion, electrocoagula-
tion and/or clipping was performed on the exposed vessels at the ulcer bed of ESD for the purpose of preventing postoperative bleeding. During and following ESD, proton-pump inhibitor, potassium-competitive acid blocker, or histamine-2 receptor antagonist was administered to all patients according to the selection of each doctor. Based on the Japanese guidelines available in Japan since 2012 [31], the clinicians decided whether antithrombotic agents should be temporarily stopped or not, and whether heparin bridging therapy should be conducted or not. Scheduled second-look endoscopy depended on the institution.

**Study 1: Comparison of the Bleeding Risk following ESD for EGC between Surgically Altered and Whole Stomach**

We evaluated the bleeding risk following ESD for EGC in surgically altered stomach compared with whole stomach. Furthermore, the bleeding risk following ESD in each type of surgically altered stomach (gastric remnant after distal gastrectomy [DG], that after proximal gastrectomy [PG], gastric conduit, and others), with reference to whole stomach, was evaluated. Bleeding following ESD was defined as active bleeding confirmed by emergent endoscopy, which was performed due to hematemesis, melena, and progression of anemia (≥2 g/dL decrease of hemoglobin), until 28 days following ESD.

**Study 2: Application of BEST-J Score and Factors Associated with Bleeding following ESD for EGC in Patients with Surgically Altered Stomach**

First, the BEST-J score was applied to patients with surgically altered stomach, and its discriminative ability for bleeding following ESD was evaluated. Subsequently, factors associated with bleeding following ESD were examined in such patients. Candidate factors were age ≥75 years, male sex, ischemic heart disease, liver cirrhosis, chronic kidney disease (CKD) with hemodialysis, aspirin, P2Y12 receptor antagonist (P2Y12RA), cilostazol, warfarin, direct oral anticoagulant (DOAC), discontinuation of antithrombotic agents (each kind of agents), heparin bridging therapy, replacement of antiplatelet agents, type of surgically altered stomach (gastric remnant after PG, gastric conduit, and others, compared with gastric remnant after DG), multiple tumors, lower third in tumor location, tumor size >30 mm, undifferentiated type, tumor invasion into submucosa ≥500 µm (SM2), ulceration, ESD procedure time >120 min, piecemeal resection, and second-look endoscopy. Lower third in tumor location was defined as the center of the tumor in gastric antrum, irrespective of the type of surgically altered stomach.

**Statistical Analyses**

Categorical variables were summarized as the count and proportion, and categorical data were compared using the χ² test. The threshold for significance was p < 0.05. All statistical analyses were performed using SPSS version 23.0 for Windows software (IBM Corp., Armonk, NY, USA).

In study 1, bleeding risk of surgically altered stomach, compared with whole stomach following ESD was evaluated using the logistic regression model. The risk was adjusted by 22 variables in the adjusted model: age ≥75 years, male sex, comorbidities (ischemic heart disease, liver cirrhosis, and CKD with hemodialysis), antithrombotic therapy (aspirin, P2Y12RA, cilostazol, warfarin,
DOAC, discontinuation of antithrombotic agents, heparin bridging therapy, and replacement of antiplatelet agents), lesion characteristics (multiple tumors, lower third in tumor location, tumor size >30 mm, undifferentiated type, SM2, and ulceration), and procedures (ESD procedure time >120 min, piecemeal resection, and second-look endoscopy). Risk of each type of surgically altered stomach was also adjusted by 22 variables in the adjusted model 2.

In study 2, the discriminative ability for bleeding following ESD was evaluated by the C-statistic. Factors associated with bleeding following ESD in patients with surgically altered stomach were evaluated using the logistic regression model. Variables with $p < 0.05$ in the univariate analysis were entered into the multivariate model.

### Table 1. Baseline characteristics of the enrolled patients

|                                | Surgically altered stomach (n = 445) | Whole stomach (n = 10,320) | p value |
|--------------------------------|-------------------------------------|---------------------------|---------|
| Age ≥75 years, n (%)           | 193 (43.4)                          | 4,184 (40.5)              | 0.237   |
| Sex, n (%)                     |                                     |                           |         |
| Male                           | 380 (85.4)                          | 7,660 (74.2)              | <0.001  |
| Female                         | 65 (14.6)                           | 2,660 (25.8)              |         |
| Comorbidities, n (%)           |                                     |                           |         |
| Ischemic heart disease         | 14 (3.1)                            | 730 (7.1)                 | 0.001   |
| Liver cirrhosis                | 5 (1.1)                             | 192 (1.9)                 | 0.363   |
| CKD with hemodialysis          | 3 (0.7)                             | 155 (1.5)                 | 0.222   |
| Antithrombotic therapy, n (%)  |                                     |                           |         |
| Aspirin                        | 28 (6.3)                            | 981 (9.5)                 | 0.023   |
| P2Y12RA                        | 17 (3.8)                            | 460 (4.5)                 | 0.629   |
| Cilostazol                     | 12 (2.7)                            | 236 (2.3)                 | 0.519   |
| Warfarin                       | 10 (2.2)                            | 326 (3.2)                 | 0.330   |
| DOAC                           | 12 (2.7)                            | 253 (2.5)                 | 0.753   |
| Interruption of antithrombotic agents, n (%) |                                     |                           |         |
| One kind of agent              | 52 (11.7)                           | 1,215 (11.8)              | 0.836   |
| Two kinds of agents            | 6 (1.3)                             | 181 (1.8)                 |         |
| Three kinds of agents          | 0 (0.0)                             | 10 (0.1)                  |         |
| Heparin bridging               | 16 (3.6)                            | 429 (4.2)                 | 0.618   |
| Replacement of antiplatelet agents | 4 (0.9)                          | 121 (1.2)                 | 0.820   |
| Lesion, n (%)                  |                                     |                           |         |
| Multiple tumors                | 41 (9.2)                            | 1,294 (12.5)              | 0.042   |
| Lower third in tumor location  | 66 (14.8)                           | 4,688 (45.4)              | <0.001  |
| Undifferentiated type          | 34 (7.6)                            | 506 (4.9)                 | 0.011   |
| Tumor size >30 mm              | 37 (8.3)                            | 1,217 (11.8)              | 0.026   |
| SM2                            | 38 (8.5)                            | 655 (6.3)                 | 0.071   |
| Ulceration (scar)              | 55 (12.4)                           | 977 (9.5)                 | 0.045   |
| Procedure, n (%)               |                                     |                           |         |
| Procedure time >120 min        | 113 (25.5)                          | 1,886 (18.3)              | <0.001  |
| Piecemeal resection            | 9 (2.0)                             | 61 (0.6)                  | 0.002   |
| Second-look endoscopy          | 303 (68.1)                          | 7,384 (71.6)              | 0.119   |
| Type of surgically altered stomach |                                  |                           |         |
| Gastric remnant after DG       | 276 (62.0)                          | –                         | –       |
| Gastric remnant after PG        | 45 (10.1)                           | –                         | –       |
| Gastric conduit                | 79 (17.8)                           | –                         | –       |
| Others                         | 45 (10.1)                           | –                         | –       |

CKD, chronic kidney disease; DG, distal gastrectomy; DOAC, direct oral anticoagulant; PG, proximal gastrectomy; P2Y12RA, P2Y12 receptor antagonist; SM2, submucosal invasion ≥500 µm from the muscularis mucosa.

### Result

**Baseline Characteristics and the Bleeding Rates**

Of the total of 11,452 patients who experienced ESD for EGC, we excluded 687 patients who met the exclusion criteria. Among these enrolled patients, the numbers of patients with surgically altered and whole stomach were 445 and 10,320, respectively (Fig. 1). Patients with surgically altered stomach consisted of 276 patients with gastric remnant after DG, 45 with that after PG, 79 with gastric conduit, and 45 with others (Table 1). The bleeding...
rate following ESD for EGC was 4.9% in patients with surgically altered stomach (Fig. 2). In detail, the bleeding rates in patients with gastric remnant after DG, that after PG, gastric conduit, and others were 4.7%, 8.9%, 3.8%, and 4.4%, respectively, the difference of which was not statistically significant ($p = 0.622$).

Study 1: Comparison of the Bleeding Risk following ESD for EGC between Surgically Altered and Whole Stomach

We conducted two multivariate analyses. In the adjusted model 1, the bleeding risk of surgically altered stomach following ESD for EGC, with reference to whole stomach, was 1.37 (0.87–2.17) ($p = 0.176$), which was not statistically significant. In the adjusted model 2, the bleeding risk of surgically altered stomach following ESD for EGC, with reference to whole stomach, was 1.89 (0.64–5.54) ($p = 0.249$), which was also not statistically significant.

Table 2. Risk of bleeding following ESD for EGC in patients with surgically altered stomach compared with whole stomach

|                          | Crude OR (95% CI) | p value | Adjusted model 1 OR (95% CI) | p value | Adjusted model 2 OR (95% CI) | p value |
|--------------------------|------------------|---------|-----------------------------|---------|-----------------------------|---------|
| Whole stomach            | 1 (Reference)    |         | 1 (Reference)               |         | 1 (Reference)               |         |
| Surgically altered stomach | 1.05 (0.68–1.62) | 0.842   | 1.37 (0.87–2.17)            | 0.176   |                              |         |
| Whole stomach            | 1 (Reference)    |         |                             |         |                             |         |
| Gastric remnant after DG | 0.99 (0.57–1.75) | 0.983   | 1.42 (0.79–2.57)            | 0.240   |                              |         |
| Gastric remnant after PG | 1.96 (0.70–5.50) | 0.200   | 1.89 (0.64–5.54)            | 0.249   |                              |         |
| Gastric conduit          | 0.79 (0.25–2.53) | 0.695   | 0.96 (0.29–3.17)            | 0.940   |                              |         |
| Others                   | 0.94 (0.23–3.87) | 0.926   | 1.21 (0.28–5.21)            | 0.795   |                              |         |

CKD, chronic kidney disease; CI, confidence interval; DG, distal gastrectomy; DOAC, direct oral anticoagulant; EGC, early gastric cancer; ESD, endoscopic submucosal dissection; OR, odds ratio; PG, proximal gastrectomy; P2Y12RA, P2Y12 receptor antagonist; SM2, submucosal invasion ≥500 µm from the muscularis mucosa. *Adjusted by age ≥75 years, male sex, ischemic heart disease, liver cirrhosis, and CKD with hemodialysis, aspirin, P2Y12RA, cilostazol, warfarin, DOAC, interruption of antithrombotic agents, heparin bridging therapy, replacement of antiplatelet agents, multiple tumors, lower third in tumor location, tumor size >30 mm, undifferentiated type, SM2, ulceration, ESD procedure time >120 min, piecemeal resection, and second-look endoscopy.
stomach, was not significant (odds ratio [OR], 1.37; 95% confidence interval [CI], 0.87–2.17) (Table 2). When each type of surgically altered stomach was included in the multivariate model (adjusted model 2), no significant results were also acquired (Table 2).

**Study 2: Application of BEST-J Score and Factors Associated with Bleeding following ESD for EGC in Patients with Surgically Altered Stomach**

Table 3 shows the bleeding rates in the risk score and classification of the BEST-J score after applying the BEST-J score for patients with surgically altered stomach. The bleeding rates following ESD in the low-, intermediate-, high-, and very high-risk categories were 4.2%, 3.3%, 8.0%, and 60.0%, respectively. The C-statistics of the risk score and classification in the BEST-J score for bleeding following ESD were 0.57 (95% CI, 0.43–0.71) and 0.58 (95% CI, 0.45–0.72), respectively, which indicates modest discriminative ability.

The results of univariate and multivariate logistic regression analyses for factors associated with bleeding following ESD for EGC in patients with surgically altered stomach are presented in Table 4. In the univariate analysis, significant factors for bleeding following ESD for EGC in patients with surgically altered stomach were ischemic heart disease, P2Y12RA, and warfarin. Regarding the type of surgically altered stomach, the risk of gastric remnant after PG, gastric conduit, and others for bleeding, with reference to gastric remnant after DG, was not statistically significant. Multivariate analysis showed that independent risk factors for bleeding following ESD in patients with surgically altered stomach were ischemic heart disease (OR, 7.52; 95% CI, 2.00–28.25) and P2Y12RA (OR, 4.81; 95% CI, 1.21–19.14) (Table 4). Warfarin tended to be associated with bleeding (OR, 3.74; 95% CI, 0.63–22.26), but it did not reach statistical significance (p = 0.147).

The relationship between bleeding following ESD and each status of P2Y12RA was also investigated. In the result, the bleeding rates in the interruption, replacement to aspirin/cilostazol, and continuation of P2Y12RA were 9.1% (1/11), 33.3% (1/3), and 33.3% (1/3), respectively.

**Discussion/Conclusion**

Despite the fact that many studies have investigated and discussed bleeding following gastric ESD in patients with whole stomach [10–12, 32], few studies have evaluated the details of bleeding following gastric ESD in patients with surgically altered stomach, mainly due to the small numbers of cases in previous studies [14–21]. Thus, the present study evaluated it using the data of a large-scale multicenter study.

The present study included some clinical implications. First, we revealed that the bleeding risk of surgically altered stomach following ESD for EGC was not significant, compared with whole stomach. Similar results were obtained when surgically altered stomach was subdivided into various types. Furthermore, the bleeding risk of various types of surgically altered stomach, with reference to gastric remnant after DG, was not significant. In surgically altered stomach, bile reflux to the gastric remnant is frequently observed in cases with DG [33]. It has been reported that bile acids and pancreatic proteolytic enzymes can damage the gastric mucosa [33, 34]; however, we found that its influence on the incidence of bleeding events following ESD may be small.

Second, the discriminative ability of the BEST-J score, which had been developed from patients with whole...
Table 4. Risk factors of bleeding following ESD for EGC in patients with surgically altered stomach

| Risk Factor                                      | Crude OR (95% CI) | p value | Adjusted OR (95% CI) | p value |
|--------------------------------------------------|-------------------|---------|-----------------------|---------|
| Age                                              |                   |         |                       |         |
| ≥75 years                                        | 1.60 (0.68–3.80)  | 0.282   | 7.52 (2.00–28.25)     | 0.003   |
| Sex                                              |                   |         |                       |         |
| Male                                             | 1.75 (0.40–7.67)  | 0.458   |                       |         |
| Ischemic heart disease                           |                   |         |                       |         |
| Yes                                              | 9.18 (2.63–32.09) | 0.001   | 7.52 (2.00–28.25)     | 0.003   |
| Liver cirrhosis                                  | –                 | –       |                       | –       |
| CKD with hemodialysis                            | –                 | –       |                       | –       |
| Aspirin                                          |                   |         |                       |         |
| Yes                                              | 0.70 (0.09–5.39)  | 0.731   | 4.61 (1.22–17.43)     | 0.026   |
| P2Y12RA                                          |                   |         |                       |         |
| Yes                                              | 4.61 (1.22–17.43) | 0.024   | 4.81 (1.21–19.14)     | 0.026   |
| Cilostazol                                       |                   |         |                       |         |
| Yes                                              | 1.78 (0.22–14.47) | 0.588   | 1.78 (0.22–14.47)     | 0.588   |
| Warfarin                                         |                   |         |                       |         |
| Yes                                              | 5.19 (1.03–26.03) | 0.045   | 3.74 (0.63–22.26)     | 0.147   |
| DOAC                                             |                   |         |                       |         |
| Yes                                              | 1.78 (0.22–14.47) | 0.588   |                       |         |
| Discontinuation of antithrombotic agents          |                   |         |                       |         |
| Each kind of agents                              | 1.60 (0.65–3.93)  | 0.306   |                       |         |
| Heparin bridging therapy                         |                   |         |                       |         |
| Yes                                              | 2.92 (0.62–13.74) | 0.175   |                       |         |
| Replacement of antiplatelet agents               |                   |         |                       |         |
| Yes                                              | 6.67 (0.67–66.84) | 0.107   |                       |         |
| Type of surgically altered stomach               |                   |         |                       |         |
| Remnant after PG                                 | 1.97 (0.61–6.35)  | 0.254   |                       |         |
| Gastric conduit                                  | 0.80 (0.22–2.88)  | 0.731   |                       |         |
| Others                                           | 0.94 (0.21–4.32)  | 0.938   |                       |         |
| The number of tumors                             |                   |         |                       |         |
| Multiple                                         | 1.60 (0.45–5.65)  | 0.466   |                       |         |
| Tumor location                                   |                   |         |                       |         |
| Lower-third                                      | 1.75 (0.62–4.91)  | 0.291   |                       |         |
| Tumor size                                       |                   |         |                       |         |
| >30 mm                                           | 2.63 (0.84–8.21)  | 0.097   |                       |         |
| Tumor differentiation                            |                   |         |                       |         |
| Undifferentiated                                 | 1.22 (0.27–5.46)  | 0.793   |                       |         |
| Tumor depth                                      |                   |         |                       |         |
| SM2                                              | 1.08 (0.24–4.79)  | 0.924   |                       |         |
| Ulcerationa                                      |                   |         |                       |         |
| Positive                                         | 1.22 (0.27–5.46)  | 0.793   |                       |         |
| ESD procedure timea                              |                   |         |                       |         |
| >120 min                                         | 1.73 (0.70–4.23)  | 0.233   |                       |         |
| Resection type                                    |                   |         |                       |         |
| Piecemeal                                        | 2.47 (0.30–20.67) | 0.404   |                       |         |
| Second-look endoscopy                            |                   |         |                       |         |
| Yes                                              | 0.81 (0.33–1.98)  | 0.646   |                       |         |

CKD, chronic kidney disease; CI, confidence interval; DOAC, direct oral anticoagulant; EGC, early gastric cancer; ESD, endoscopic submucosal dissection; OR, odds ratio; PG, proximal gastrectomy; P2Y12RA, P2Y12 receptor antagonist; SM2, submucosal invasion ≥500 µm from the muscularis mucosa. aThere were 2 and 1 missing cases in ulceration and ESD procedure time, respectively.
stomach [22], for bleeding was not satisfactory in surgically altered stomach. The C-statistics of the risk score and classification in the BEST-J score were 0.57 and 0.58, respectively, which were lower than 0.70 that is considered sufficient to make clinically useful individual predictions [35]. Thus, caution is needed for applying the BEST-J score for patients with surgically altered stomach.

Subsequently, we evaluated the risk factors for bleeding following ESD for EGC in patients with surgically altered stomach. Among the candidate variables, ischemic heart disease and P2Y12RA were significant risk factors. Regarding ischemic heart disease, a previous systematic review revealed cardiopathy (ischemic heart disease in most studies) as one of the risk factors for bleeding following ESD, mainly in patients with whole stomach [36]. However, this systematic review showed that its risk is most probably associated with the use of antithrombotic agents [36]. In the present study, when adjusted by all antithrombotic agents, the risk of ischemic heart disease remained significant (data not shown). Thus, this factor itself may have a potential risk for bleeding in patients with surgically altered stomach. Although the mechanism is unclear, clinicians should pay attention to the bleeding risk in such patients. Meanwhile, P2Y12RA is a well-known risk factor for bleeding following ESD in patients with whole stomach [22, 37]. Then, should P2Y12RA be interrupted before ESD? Although the bleeding rate in patients with P2Y12RA was lower in interruption than in replacement with aspirin/cilostazol or continuation, interruption may lead to thromboembolism [32]. Considering the more serious condition in thromboembolism [31], interruption of P2Y12RA may not be recommended in the current status; however, it is difficult to make a definite conclusion from this study and further studies are required.

The strength in the present study is that this study included the largest number of cases. Indeed, the number of patients with surgically altered stomach is over three times larger than that in the largest study to date [18]. This enabled us to perform a multivariate analysis of risk factors for bleeding following ESD for EGC in patients with surgically altered stomach.

This study has several limitations. First, this is a retrospective style, which may include a potential bias. Second, we did not investigate whether the lesion was on the submucosal/interstitial site or not. Although no significant results on bleeding following ESD were shown in the previous study [18], this location may have a potential to be a confounding factor for the risk of bleeding. Third, despite the largest cohort to date, the sample size is still not large enough, which led to relatively wide 95% CIs in the multivariate logistic regression analysis. However, our study results are likely significant because this is the first analysis of the details of bleeding following ESD for EGC in patients with surgically altered stomach by using the data of a multicenter cohort. Fourth, the type of acid-suppressive agents was not evaluated in this study. Although it was proven that the type affected the bleeding risk following gastric ESD [38, 39], the methods of administrating acid-suppressive agents were not controlled and various patterns were shown. Thus, it was difficult to evaluate the relationship between the type of acid-suppressive agents and bleeding risk. Lastly, CKD with hemodialysis, which was proven to be a risk factor for bleeding following ESD in whole stomach [22], could not be calculated in the analysis of risk factors for bleeding in patients with surgically altered stomach due to the very small number of cases of this disease.

In conclusion, the bleeding risk of surgically altered stomach following ESD for EGC did not significantly differ from that of whole stomach. Furthermore, we first found that the risk factors for ESD in patients with surgically altered stomach were ischemic heart disease and P2Y12RA. These findings may provide some insights in this field.

Acknowledgments

We thank all collaborators in the Fight-Japan study group for the enrollment of patients and data collection: Sho Shiroma (Cancer Institute Hospital, Japanese Foundation for Cancer Research), Hiroyuki Ono (Shizuoka Cancer Centre), Kazuhiro Matsunaga and Shigennori Wakisaka (Ishikawa Prefectural Central Hospital), Shusei Fukunaga, Masaki Ominami, and Taishi Sakai (Osaka City University Graduate School of Medicine), Yuku Miura (The University of Tokyo), Minami Hashimoto, Jum Nakamura, and Ko Watanabe (Fukushima Medical University Hospital), Ryusuke Ariyoshi (Kobe University Graduate School of Medicine), Yutaka Okagawa, Takeyoshi Minagawa, and Ryoji Fujii (Tosania Hospital), Takao Maeika and Kazuhiro Fukatsu (Wakayama Medical University), Yoichi Hiasa (Ehime University Graduate School of Medicine), Daisuke Chinda, Hidezumi Kikuchi, and Tetsuya Tatsuta (Hirosaki University Hospital), Atsushi Goto (Yamaguchi University Graduate School of Medicine), Daisuke Maruoka, Kenichiro Okimoto, and Naoki Akizue (Chiba University Graduate School of Medicine), Tomoaki Yamashita, Takehisa Suekane, and Yu Yasui (Osaka City General Hospital), Tatsunobu Nishida and Masashi Yamamoto (Toyonaka Municipal Hospital), Keiichi Hashiguchi and Naoyuki Yamaguchi (Nagasaki University Hospital), Yoichi Akazawa and Hiroyuki Komori (Juntendo University School of Medicine), Yoshiaki Tsuji, Hideki Iijima, and Tetsuo Takehara (Osaka University Graduate School of Medicine), Masaki Murata

Bleeding after Endoscopic Submucosal Dissection in Surgically Altered Stomach

Digestion 2022;103:428–437
DOI: 10.1159/000526865
Statement of Ethics

This study protocol was reviewed and approved by the Ethics Committee of Tohoku University Graduate School of Medicine (2018-1-48) (including approval of Ethics Committee for the University of Tokyo by central Ethics Committee of Tohoku University Graduate School of Medicine), the Ethics Committee of the Cancer Institute Hospital (2018-1163), the Institutional Review Board of Shizuoka Cancer Centre (T30-15-30-1-3), the Ethics Committee of Toranomon Hospital (1683), the Institutional Review Board of Ishikawa Prefectural Central Hospital (1131), Ethical Committee of Osaka City University Graduate School of Medicine (4089), the Ethics Committee of Fukushima Medical University (30101), the Ethics Committee of the Jikei University School of Medicine for Biomedical Research (30-170 [9191]), the Ethical Committee on Clinical Investigation of Kobe University Hospital (180126), the Institutional Review Board of Tonan Hospital (338), Research Ethics Committee of Wakayama Medical University (2018-2384), the Ethics Committee of Ehime University Graduate School of Medicine (1807001), the Ethics Committee of Ehime Prefectural Central Hospital (No. 30-25), the Ethics Committee of Osaka General Medical Center (30-S03-004), the Ethics Committee of Hiroaki University Graduate School of Medicine (2018-1079), the Ethics Committee of Fukui Prefectural Hospital (18-15), Institutional Review Board Yamaguchi University Hospital (H30-058), Research Ethics Committee of the Graduate School of Medicine and School of Medicine, Chiba University (3189), Osaka City General Hospital Research Ethics Review Board (1805018), the Institutional Review Board of Toyonaka Municipal Hospital (2018-04-04), Ethics Committee of Nagasaki University Hospital (18091014), Hospital Ethics Committee Juntendo University Hospital (18-097), Osaka University Clinical Research Review Committee (18056), Shiga University of Medical Science Research Ethics Committee (R2018-029), Kansai Rosai Hospital IRB (18D046g), Institutional Review Board for Ethics in Clinical Study of Saitama Medical Centre, Saitama Medical University (1940), the Ethics Committee of National Centre for Global Health and Medicine (NCGM-G-002554-00), the Ethics Committee of Kanazawa University School of Medicine (2018-043-2823), the Ethics Committee of the University of Tsukuba (H30-107), the Ethics Committee of Gunma University Graduate School of Medicine (H2018-102), the Ethics Committee of Shuto General Hospital (H30-5), and the Institutional Review Board of National Hospital Organization Hakodate National Hospital (H30-0514003). The need for obtaining informed consent from each patient was waived via the opt-out method on each participating institution’s website. Informed consent of ESD was obtained from all patients before the procedure in accordance with the institutional protocol.

Conflict of Interest Statement

Mitsuhiro Fujishiro declared that he received lecture honoraria from Takeda Pharmaceutical, EA Pharma, and Nihon Pharmaceutical, and his department received research grants from HOYA Pentax, EA Pharma, Eisai, Taiho Pharmaceutical, AbbVie GK, Nippon Kayaku, Chugai Pharmaceutical, Gilead Sciences, KYORIN Pharmaceutical, and Mitsubishi Tanabe Pharma outside the submitted work.

Funding Sources

The current study was partially supported by the Japanese Foundation for Research and Promotion of Endoscopy Grant.

Author Contributions

Conception and design; analysis and interpretation of data; and drafting of the manuscript: Hiroyuki Odagiri and Waku Hatta; acquisition of data: Hiroyuki Odagiri, Waku Hatta, Yosuke Tsuji, Toshiyuki Yoshio, Yohei Yabuuchi, Daisuke Kikuchi, Shigetsugu Tsuji, Yasuaki Nagami, Takuto Hikichi, Masakuni Kobayashi, Yo shinori Morita, Tetsuya Sumiyoshi, Mikitaka I guchi, Hideomi Tomida, Takuya Inoue, Tatsuya Mikami, Kenkei Hasatani, Jun Nishikawa, Tomoaki Matsumura, Hiroko Nebiki, Dai Nakamatsu, Ken Ohnita, Hiroya Ueyama, Yoshiito Hayashi, Mitsushige Sugimoto, Shinjiro Yamaguchi, Tomoki Michida, Tomoyuki Yada, Yoshiro Ashina, Toshiaki Narasaki, Shiko Kuribayashi, Shu Kiyotoki, and Katsuhiro Mabe; critical revision of the manuscript: Haruhi Suzuki and Mitsuhiro Fujishiro; statistical analysis: Waku Hatta; study supervision: Mitsuhiro Fujishiro, Atsushi Ma moto, Shinjiro Yamaguchi, Tomoki Michida, Tomoyuki Yada, Yoshiro Ashina, Toshiaki Narasaki, Shiko Kuribayashi, Shu Kiyotoki, and Katsuhiro Mabe; revision of the manuscript: Waku Hatta; study supervision: Mitsuhiro Fujishiro, Atsushi Mas amune, and Shu Hoteya. All authors listed have contributed substantially to the design, data collection and analysis, and editing of the manuscript.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

References

1. Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001 Feb;48(2):225–9.
2. Hatta W, Gotoda T, Koike T, Masamune A. History and future perspectives in Japanese guidelines for endoscopic resection of early gastric cancer. Gastrointest Endosc. 2020 Jan;91(1):180–90.
3. Gotoda T. Endoscopic resection of early gastric cancer. Gastric Cancer. 2007;10(1):1–11.
4. Hatta W, Gotoda T, Koike T, Masamune A. Management following endoscopic resection in elderly patients with early-stage upper gastrointestinal neoplasia. Gastrointest Endosc. 2020 Sep; 82(6):861–73.
Bleeding after Endoscopic Submucosal Dissection in Surgically Altered Stomach

5 Isomoto H, Shikuwa S, Yamaguchi N, Fukuda E, Ikeda K, Nishiyama H, et al. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut. 2009 Mar;58(3):331–6.

6 Hatta W, Gotoda T, Koike T, Masamune A. A recent argument for the use of endoscopic submucosal dissection for early gastric cancers. Gut Liver. 2020 Jul;14(4):412–22.

7 Ogata Y, Hatta W, Ohara Y, Koike T, Abe H, Saito M, et al. Predictors of early and late mortality after the treatment for early gastric cancers. Dig Endosc. 2022 May;34(4):816–25.

8 Rembacken BJ, Gotoda T, Fujii T, Axon AT. Endoscopic mucosal resection. Endoscopy. 2001 Aug;33(8):709–18.

9 Tanigawa N, Nomura E, Lee SW, Kamoshida T, Hirai S, et al. Antithrombotic therapy for early gastric cancer in the remnant stomach after distal gastrectomy. J Gastroenterol. 2019 Jun;54(6):511–20.

10 Nishide N, Ono H, Kakushima N, Takezawa K, Tanaka M, Matsubayashi H, et al. Clinical outcomes of endoscopic submucosal dissection for early gastric cancer in remnant stomach. J Gastroenterol. 2020 Jul;55(7):873–83.

11 Tomida H, Hirasawa K, Koh R, Ikeda R, Fukuchi T, Kobayashi R, et al. Postoperative bleeding in patients on antithrombotic therapy after gastric endoscopic submucosal dissection. World J Gastroenterol. 2017 Aug;23(30):5557–66.

12 Takeuchi T, Ota K, Harada S, Edogawa S, Kojima Y, Tokioka S, et al. The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. BMC Gastroenterol. 2013 Sep;13:136.

13 Barakat M, Seif M, Abdelfatah MM, Ofosu A, Carr-Locke DL, Othman MO. Endoscopic submucosal dissection for early neoplastic lesions in the surgically altered stomach: a systematic review and meta-analysis. Surg Endosc. 2019 Aug;33(8):2381–95.

14 Lee JY, Min BH, Lee JG, Noh D, Lee JH, Rhee PL, et al. Endoscopic submucosal dissection for early gastric neoplasia occurring in the remnant stomach after distal gastrectomy. Clin Endosc. 2016 Mar;49(2):182–6.

15 Song BG, Kim GH, Lee BE, Jeon HK, Baek DH, Song GA. Endoscopic submucosal dissection of gastric epithelial neoplasms after partial gastrectomy: a single-center experience. Gastrointest Res Pract. 2017;2017:6385283.

16 Nonaka S, Oda I, Makazu M, Haruyama S, Abe S, Suzuki H, et al. Endoscopic submucosal dissection for early gastric cancer in the remnant stomach after gastrectomy. Gastrointest Endosc. 2013 Jul;78(1):63–72.

17 Hoteya S, Iizuka T, Kikuchi D, Yahagi N. Clinical advantages of endoscopic submucosal dissection for gastric cancers in remnant stomach: a systematic review and meta-analysis. Gastrointest Endosc. 2019 Jan;80(1):17–20.

18 Yabuuchi Y, Kakushima N, Takizawa K, Tanaka M, Kawata N, Yoshida M, et al. Short- and long-term outcomes of endoscopic submucosal dissection for early gastric cancer in the remnant stomach after gastrectomy. J Gastroenterol. 2019 Jun;54(6):511–20.

19 Hatta W, Tsuji Y, Yoshio T, Hoteya S, Yohsizaki T, Kawara F, et al. Endoscopic submucosal dissection for early gastric cancer in anastomosis site after distal gastrectomy. Gastro Cancer. 2014 Apr;17(2):371–6.

20 Takeuchi T, Ota K, Harada S, Edogawa S, Kojima Y, Tokioka S, et al. Rebleeding in patients with delayed bleeding after endoscopic submucosal dissection for early gastric cancer. J Gastroenterol Hepatol. 2021 Mar;36(3):703(3):476–84.

21 Hashimoto M, Hatta W, Tsuji Y, Yoshio T, Yabuuchi Y, Hoteya S, et al. Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score. Gut. 2021 Mar;70(3):476–84.

22 Hatta W, Tsuji Y, Yoshio T, Kakushima N, Hoteya S, Doyama H, et al. Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score. Gut. 2021 Mar;70(3):476–84.

23 Shimohori M, Hotta W, Tsuji Y, Yoshio T, Yabuuchi Y, Hoteya S, et al. Rebleeding in patients with delayed bleeding after endoscopic submucosal dissection for early gastric cancer. Dig Endosc. 2021 Nov;33(7):1120–30.

24 Shiroma S, Hatta W, Tsuji Y, Yoshio T, Yabuuchi Y, Hoteya S, et al. Timing of bleeding and thromboembolism associated with endoscopic submucosal dissection for gastric cancer in Japan. J Gastroenterol Hepatol. 2020 Oct;35(10):2769–77.

25 Nagami Y, Hatta W, Tsuji Y, Yoshio T, Kakushima N, Hoteya S, et al. Antithrombotics increase bleeding after endoscopic submucosal dissection for gastric cancer: nationwide propensity score analysis. Dig Endosc. 2022 Jul;34(5):974–83.

26 Yabuuchi Y, Hotta W, Tsuji Y, Yoshio T, Kakushima N, Hoteya S, et al. Influence of hospital volume on bleeding after endoscopic submucosal dissection for early gastric cancer in Japan: a multicenter propensity score-matched analysis. Surg Endosc. 2022 Jun;36(6):4004–13.

27 Sugiyama Y, Sohma H, Ozawa M, Hada R, Mikami Y, Konn M, et al. Regurgitant bile acids and mucosal injury of the gastric remnant after partial gastrectomy. Am J Surg. 1987 Apr;153(4):399–403.

28 Pencina MJ, D’Agostino RB Sr., Demler OV. Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for nomal variables and nested models. Stat Med. 2012 Jan 30;31(2):101–13.

29 Libanio D, Costa MN, Pimentel-Nunes P, Dinis-Ribeiro M. Risk factors for bleeding after endoscopic submucosal dissection: a systematic review and meta-analysis. Gastrointest Endosc. 2016 Oct;84(4):572–86.

30 Ono S, Fujishiro M, Yoshida N, Doyama H, Kamoshida T, Hirai S, et al. Thienopyridine derivatives as risk factors for bleeding following high risk endoscopic treatments: Safe Treatment on Antiplatelets (STRAP) study. Endoscopy. 2015 Jul;47(7):632–7.

31 Ueno N, Takeuchi Y, Yamada T, Iishihara R, Ogiyama H, Yamamoto S, et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol. 2007 Aug;102(8):1610–6.

32 Abe H, Hatta W, Ogata Y, Koike T, Saito M, Jin X, et al. Prevention of delayed bleeding with vonoprazan in upper gastrointestinal endoscopic treatment. J Gastroenterol. 2021 Jul;56(7):640–50.